Cost-effectiveness of childhood rotavirus vaccination in Germany

Vaccine

Volumn 32, Issue 17, 2014, Pages 1964-1974

  Aidelsburger, Pamela ^a   Grabein, Kristin ^a   Böhm, Katharina ^a   Dietl, Markus ^a   Wasem, Jürgen ^b   Koch, Judith ^c   Ultsch, Bernhard ^c,d   Weidemann, Felix ^c   Wichmann, Ole ^c  

^a CAREM GmbH ^*  (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c ROBERT KOCH INSTITUTE   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cost effectiveness; Germany; Health economic evaluation; Markov model; Rotavirus; Vaccination

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; GERMANY; HEALTH CARE SYSTEM; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; INCIDENCE; NONHUMAN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); ROTAVIRUS; ROTAVIRUS INFECTION; VACCINATION;

COST EFFECTIVENESS; GERMANY; HEALTH ECONOMIC EVALUATION; MARKOV MODEL; ROTAVIRUS; VACCINATION;

CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; GASTROENTERITIS; GERMANY; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; MARKOV CHAINS; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINATION; VACCINES, ATTENUATED;

EID: 84896317254     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.01.061     Document Type: Article

References (32)

1. Gabutti G., Marsella M., Lazzara C., Fiumana E., Cavallaro A., Borgna-Pignatti C. Epidemiology and burden of rotavirus-associated hospitalizations in Ferrara, Italy. J Prev Med Hyg 2007, 48:5-9.
2. Statistisches Bundesamt Tabelle: Meldepflichtige Krankheiten absolut und je 100.000 Einwohner. Gliederungsmerkmale: Jahre, Region, Alter, Geschlecht. Gesundheitsberichterstattung des Bundes 2012.
3. Robert Koch-Institut Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten für 2010 2011, Robert Koch-Institut, Berlin, 176-81.
4. Block S.L., Vesikari T., Goveia M.G., Rivers S.B., Adeyi B.A., Dallas M.J., et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics 2007, 119:11-18.
5. Clark H.F., Burke C.J., Volkin D.B., Offit P., Ward R.L., Bresee J.S., et al. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. Pediatr Infect Dis J 2003, 22:914-920.
6. Clark H.F., Bernstein D.I., Dennehy P.H., Offit P., Pichichero M., Treanor J., et al. Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants. J Pediatr 2004, 144:184-190.
7. Ciarlet M., He S., Lai S., Petrecz M., Yuan G., Liu G.F., et al. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity. Pediatr Infect Dis J 2009, 28:177-181.
8. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354:23-33.
9. Vesikari T., Itzler R., Karvonen A., Korhonen T., Van Damme P., Behre U., et al. RotaTeq, a pentavalent rotavirus vaccine: efficacy and safety among infants in Europe. Vaccine 2009, 28:345-351.
10. Vesikari T., Karvonen A., Korhonen T., Espo M., Lebacq E., Forster J., et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine 2004, 22:2836-2842.
11. Vesikari T., Karvonen A., Puustinen L., Zeng S.Q., Szakal E.D., Delem A., et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 2004, 23:937-943.
12. Vesikari T., Karvonen A., Prymula R., Schuster V., Tejedor J.C., Cohen R., et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007, 370:1757-1763.
13. Dennehy P.H., Brady R.C., Halperin S.A., Ward R.L., Alvey J.C., Fischer F.H., et al. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. Pediatr Infect Dis J 2005, 24:481-488.
14. Patel M.M., Haber P., Baggs J., Zuber P., Bines J.E., Parashar U.D. Intussusception and rotavirus vaccination: a review of the available evidence. Expert Rev Vaccines 2009, 8:1555-1564.
15. WHO SAGE Candidate rotavirus vaccine recommendations for consideration by the WHO Strategic Advisory Group of Experts (SAGE) on Immunization 2009, WHO SAGE.
16. Dudareva-Vizule S., Koch J., An der Heiden M., Oberle D., Keller-Stanislawski B., Wichmann O. Impact of rotavirus vaccination in regions with low and moderate vaccine uptake in Germany. Hum Vaccines Immunother 2012, 8.
17. Soriano-Gabarro M., Mrukowicz J., Vesikari T., Verstraeten T. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J 2006, 25:S7-S11.
18. Diez-Domingo J., Surinach N.L., Alcalde N.M., Betegon L., Largeron N., Trichard M. Burden of paediatric Rotavirus Gastroenteritis (RVGE) and potential benefits of a universal rotavirus vaccination programme with a pentavalent vaccine in Spain. BMC Public Health 2010, 10:469.
19. Statistisches Bundesamt Periodensterbetafeln für Deutschland. Allgemeine Sterbetafeln, abgekürzte Sterbetafeln und Sterbetafeln. 1871/1881 bis 2008/2010 2012, 383-385. Statistisches Bundesamt, Wiesbaden.
20. Vesikari T., Clark H.F., Offit P.A., Dallas M.J., DiStefano D.J., Goveia M.G., et al. Effects of the potency and composition of the multivalent human-bovine (WC3) reassortant rotavirus vaccine on efficacy, safety and immunogenicity in healthy infants. Vaccine 2006, 24:4821-4829.
21. Shim E., Galvani A.P. Impact of transmission dynamics on the cost-effectiveness of rotavirus vaccination. Vaccine 2009, 27:4025-4030.
22. Martin A., Cottrell S., Standaert B. Estimating utility scores in young children with acute rotavirus gastroenteritis in the UK. J Med Econ 2008, 11:471-484.
23. Goossens L.M., Standaert B., Hartwig N., Hovels A.M., Al M.J. The cost-utility of rotavirus vaccination with Rotarix (RIX4414) in The Netherlands. Vaccine 2008, 26:1118-1127.
24. Atchison C., Lopman B., Edmunds W.J. Modelling the seasonality of rotavirus disease and the impact of vaccination in England and Wales. Vaccine 2010, 28:3118-3126.
25. Pitzer V.E., Viboud C., Simonsen L., Steiner C., Panozzo C.A., Alonso W.J., et al. Demographic variability, vaccination, and the spatiotemporal dynamics of rotavirus epidemics. Science 2009, 325:290-294.
26. Atkins K.E., Shim E., Pitzer V.E., Galvani A.P. Impact of rotavirus vaccination on epidemiological dynamics in England and Wales. Vaccine 2012, 30:552-564.
27. Tilson L., Jit M., Schmitz S., Walsh C., Garvey P., McKeown P., et al. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland. Vaccine 2011, 29:7463-7473.
28. Martin A., Batty A., Roberts J.A., Standaert B. Cost-effectiveness of infant vaccination with RIX4414 (Rotarix(TM)) in the UK. Vaccine 2009, 27:4520-4528.
29. Melliez H., Levybruhl D., Boelle P.Y., Dervaux B., Baron S., Yazdanpanah Y. Cost and cost-effectiveness of childhood vaccination against rotavirus in France. Vaccine 2008, 26:706-715.
30. Bilcke J., Beutels P. Reviewing the cost effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources. Pharmacoeconomics 2009, 27:281-297.
31. Atkins K.E., Shim E., Carroll S., Quilici S., Galvani A.P. The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales. Vaccine 2012, 30:6766-6776.
32. Knoll S., Benter U., Vouk K., Standaert B. Health economic model on the costs and effects of rotavirus vaccination in Germany 2011, ISPOR, Madrid.